Combination antiretroviral therapy and MCL1 inhibition mitigate HTLV-1 infection in vivo

Cooney JP1,2, Allison C1,2, Doerflinger M1,2, Hickey P1,2,3, Hiron A5,6, Dagley LF2,3, Yousef J2,3, Yurick D5,6, Preston SP1,2, Einsiedel L4§, Purcell DFJ5,6§, Pellegrini M1,2§

1Division of Infectious Diseases and Immune Defence, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
2Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
3Advanced Technology & Biology, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
4Department of Medicine, Alice Spring Hospital, Alice Springs, Australia.
5Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
6The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia.

Background:
BH3 mimetics are small-molecule therapeutics designed to lower the threshold for the induction of intrinsic apoptosis, a form of cell death, by antagonising the function of pro-survival BCL-2 family members. Many blood cancers, including ATL, are recognised to be associated with elevated levels of pro-survival BCL-2 proteins marking them as attractive therapeutic targets for preferential killing. Here, we assessed the efficacy of clinical-stage BH3 mimetics, venetoclax and S63845, in combination with antiretrovirals, for the treatment of HTLV-1 infection in humanised mice.

Methods:
Humanised NOD SCID IL2γc−/− mice were adoptively transferred autologous HTLV-1-infected PBMC before administration of venetoclax or S63845 (BCL-2 or MCL-1 antagonists, respectively) for 3 weeks. Mice were administered antiretrovirals, tenofovir alafenamide and dolutegravir, to mitigate viral spread. HTLV-1c PVL and human cell number were quantified in the periphery at 3-, 5-, and 7-weeks post infection.

Results:
After three weeks of S63845 treatment, HTLV-1c PVL was undetectable in 81% of mice (13 of 16 mice) compared to 20% of control animals (3 of 15 mice) (p=0.0007). Provirus was increasingly detectable at later time points, but this was significantly delayed compared to control ((2.33wks (1.05 to 5.21), median survival (95% CI)) (p=0.0093). Venetoclax treatment did not significantly impact provirus where 54% of drug-treated mice (7 of 13 mice) had undetectable provirus compared to 42% of control mice (5 or 12 mice) at three weeks post infection (p=0.6005). S63845 treatment curtailed HTLV-1c-driven expansion of the CD4+ T cell population compared to vehicle treated mice from zero to seven weeks post-infection (5.3-fold and 26.3-fold increase, respectively, p=0.0024).

Conclusion:
We provide a rationale for the use of clinical-stage BH3 mimetics, specifically those targeting MCL-1, in combination with antiretrovirals, for the treatment of established HTLV-1 infection. Our data support the initiation of clinical trials to investigate the efficacy of this strategy against HTLV-1.

**Disclosure of Interest Statement:**
None to declare.

**Acknowledgement of Funding:**
This research was funded in part by the Australian Centre for HIV and Hepatitis Virology Research.